A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Infigratinib in Children 3 to <18 Years of Age with Achondroplasia: PROPEL 3
Details
Age
Child
Eligibility
Age 3 to <18 years of age with growth potential defined as AHV of >1.5cm/year over a period of at least 6 months.
Confirmed diagnosis of ACH via genetic testing, 6 months participation in PROPEL study prior to study entry, and able to swallow study medication.
Type of Study
Treatment
Scope
National
Locations
Childrens Hospital Colorado
Principal Investigator
Klane White, MD, MSc
Study ID
Protocol Number: 23-2112
More information available at ClinicalTrials.gov: NCT04035811
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers